Open | - |
Close | - |
Volume / Avg. | 0 / 29.188K |
Day Range | - - - |
52 Wk Range | 0.500 - 2.680 |
Market Cap | $2.476M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 42 |
Short Interest | % |
Days to Cover | 1 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Salarius Pharmaceuticals (NASDAQ: SLRX) through any online brokerage.
Other companies in Salarius Pharmaceuticals’s space includes: ZyVersa Therapeutics (NASDAQ:ZVSA), NeuBase Therapeutics (NASDAQ:NBSE), Dermata Therapeutics (NASDAQ:DRMA), Bone Biologics (NASDAQ:BBLG) and Quoin Pharmaceuticals (NASDAQ:QNRX).
The latest price target for Salarius Pharmaceuticals (NASDAQ: SLRX) was reported by HC Wainwright & Co. on Friday, March 11, 2022. The analyst firm set a price target for 4.00 expecting SLRX to rise to within 12 months (a possible 536.33% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Salarius Pharmaceuticals (NASDAQ: SLRX) is $0.6286 last updated March 18, 2024 at 4:18 PM EDT.
There are no upcoming dividends for Salarius Pharmaceuticals.
Salarius Pharmaceuticals’s Q1 earnings are confirmed for Thursday, May 9, 2024.
There is no upcoming split for Salarius Pharmaceuticals.
Salarius Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.